French medtech startup Volta Medical lands €36 million
Summary
• None It brings the total capital raised by the company to over €70 million • None The funding will help with product development, clinical trials and preparing for commercialization Justin Klein, MD, JD, co-founder and managing partner of Vensana Capital: “Volta Medical’s technology is designed to redefine how electrophysiologists make real-time decisions in pinpointing areas relevant to atrial fibrillation persistence. Theophile Mohr Durdez, Volta Medical CEO and co-founder: “There is a critical need to improve precision and consistency in cardiac ablation procedures for patients with persistent AF. We are most grateful to the teams at Vensana, Lightstone, and Gilde for their support and confidence as we partner to further validate our products and expand access to it globally.” Alongside this funding announcement, the company has appointed a new CFO – John Slump – as it ramps up expansion plans. John Slump, CFO: “I’m excited to join the Volta Medical team and am pleased with our ability to attract significant equity investment from both new and existing investors in an increasingly challenging fundraising climate. VOLTA VX1 has the potential to make a major difference in the lives of millions of people with AF, and this Series B Financing will help to accelerate its development and adoption nationally and across the globe.”